25 XP   0   0   10

Genmab A/S
Buy, Hold or Sell?

Let's analyse Genmab together

PenkeI guess you are interested in Genmab A/S. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Genmab A/S. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Genmab A/S

I send you an email if I find something interesting about Genmab A/S.

Quick analysis of Genmab (30 sec.)










What can you expect buying and holding a share of Genmab? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr483.85
Expected worth in 1 year
kr551.41
How sure are you?
95.0%

+ What do you gain per year?

Total Gains per Share
kr67.56
Return On Investment
3.3%

For what price can you sell your share?

Current Price per Share
kr2,030.00
Expected price per share
kr1,825 - kr2,171
How sure are you?
50%

1. Valuation of Genmab (5 min.)




Live pricePrice per Share (EOD)

kr2,030.00

Intrinsic Value Per Share

kr604.55 - kr2,665.11

Total Value Per Share

kr1,088.39 - kr3,148.95

2. Growth of Genmab (5 min.)




Is Genmab growing?

Current yearPrevious yearGrowGrow %
How rich?$4.5b$3.6b$620m14.6%

How much money is Genmab making?

Current yearPrevious yearGrowGrow %
Making money$155.3m$197.1m-$41.7m-26.9%
Net Profit Margin24.7%39.0%--

How much money comes from the company's main activities?

3. Financial Health of Genmab (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#16 / 1011

Most Revenue
#30 / 1011

Most Profit
#21 / 1011

Most Efficient
#62 / 1011

What can you expect buying and holding a share of Genmab? (5 min.)

Welcome investor! Genmab's management wants to use your money to grow the business. In return you get a share of Genmab.

What can you expect buying and holding a share of Genmab?

First you should know what it really means to hold a share of Genmab. And how you can make/lose money.

Speculation

The Price per Share of Genmab is kr2,030. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genmab.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genmab, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr483.85. Based on the TTM, the Book Value Change Per Share is kr16.89 per quarter. Based on the YOY, the Book Value Change Per Share is kr19.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genmab.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps1.400.1%2.980.1%2.990.1%2.280.1%1.400.1%
Usd Book Value Change Per Share1.070.1%2.410.1%2.740.1%2.580.1%1.690.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.070.1%2.410.1%2.740.1%2.580.1%1.690.1%
Usd Price Per Share307.73-351.00-362.85-311.89-218.88-
Price to Earnings Ratio54.99-34.25-51.54-70.53--28.91-
Price-to-Total Gains Ratio286.81--39.20-224.49-223.53-294.14-
Price to Book Ratio4.45-5.48-6.62-7.20-10.29-
Price-to-Total Gains Ratio286.81--39.20-224.49-223.53-294.14-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share289.884
Number of shares3
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share2.412.58
Usd Total Gains Per Share2.412.58
Gains per Quarter (3 shares)7.247.73
Gains per Year (3 shares)28.9430.90
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10291903121
20584806252
30877709383
401161060124114
501451350155145
601741640185176
702031930216207
802322220247238
902602510278269
1002892800309300

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%37.03.00.092.5%42.018.00.070.0%
Book Value Change Per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%38.02.00.095.0%44.013.03.073.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.060.00.0%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%38.02.00.095.0%44.013.03.073.3%

Fundamentals of Genmab

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Fundamental data was last updated by Penke on 2024-04-11 10:00:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Genmab A/S.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Genmab earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Genmab to the Biotechnology industry mean.
  • A Net Profit Margin of 13.7% means that kr0.14 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genmab A/S:

  • The MRQ is 13.7%. The company is making a huge profit. +2
  • The TTM is 24.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ13.7%TTM24.7%-11.0%
TTM24.7%YOY39.0%-14.3%
TTM24.7%5Y34.1%-9.4%
5Y34.1%10Y40.1%-6.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.7%-196.1%+209.8%
TTM24.7%-211.9%+236.6%
YOY39.0%-277.7%+316.7%
5Y34.1%-432.9%+467.0%
10Y40.1%-599.3%+639.4%
1.1.2. Return on Assets

Shows how efficient Genmab is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genmab to the Biotechnology industry mean.
  • 1.8% Return on Assets means that Genmab generated kr0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genmab A/S:

  • The MRQ is 1.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.8%TTM3.2%-1.4%
TTM3.2%YOY4.8%-1.6%
TTM3.2%5Y4.2%-1.0%
5Y4.2%10Y4.4%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8%-13.3%+15.1%
TTM3.2%-12.7%+15.9%
YOY4.8%-11.8%+16.6%
5Y4.2%-14.0%+18.2%
10Y4.4%-15.9%+20.3%
1.1.3. Return on Equity

Shows how efficient Genmab is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genmab to the Biotechnology industry mean.
  • 2.0% Return on Equity means Genmab generated kr0.02 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genmab A/S:

  • The MRQ is 2.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.0%TTM3.6%-1.6%
TTM3.6%YOY5.4%-1.8%
TTM3.6%5Y4.7%-1.1%
5Y4.7%10Y5.0%-0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0%-16.9%+18.9%
TTM3.6%-16.0%+19.6%
YOY5.4%-15.1%+20.5%
5Y4.7%-19.7%+24.4%
10Y5.0%-20.5%+25.5%

1.2. Operating Efficiency of Genmab A/S.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Genmab is operating .

  • Measures how much profit Genmab makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genmab to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genmab A/S:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM12.7%-12.7%
TTM12.7%YOY43.1%-30.3%
TTM12.7%5Y33.5%-20.8%
5Y33.5%10Y39.5%-6.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--290.9%+290.9%
TTM12.7%-224.4%+237.1%
YOY43.1%-288.3%+331.4%
5Y33.5%-479.5%+513.0%
10Y39.5%-625.2%+664.7%
1.2.2. Operating Ratio

Measures how efficient Genmab is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.67 means that the operating costs are kr0.67 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Genmab A/S:

  • The MRQ is 0.670. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.705. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.670TTM0.705-0.035
TTM0.705YOY0.595+0.110
TTM0.7055Y0.636+0.068
5Y0.63610Y0.591+0.046
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6703.110-2.440
TTM0.7053.266-2.561
YOY0.5953.783-3.188
5Y0.6365.657-5.021
10Y0.5917.783-7.192

1.3. Liquidity of Genmab A/S.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Genmab is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.34 means the company has kr13.34 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Genmab A/S:

  • The MRQ is 13.341. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.522. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.341TTM13.522-0.181
TTM13.522YOY13.901-0.379
TTM13.5225Y14.231-0.709
5Y14.23110Y12.576+1.655
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.3413.905+9.436
TTM13.5224.212+9.310
YOY13.9015.337+8.564
5Y14.2316.062+8.169
10Y12.5766.401+6.175
1.3.2. Quick Ratio

Measures if Genmab is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genmab to the Biotechnology industry mean.
  • A Quick Ratio of 7.33 means the company can pay off kr7.33 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genmab A/S:

  • The MRQ is 7.333. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 14.103. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.333TTM14.103-6.770
TTM14.103YOY20.284-6.181
TTM14.1035Y20.276-6.173
5Y20.27610Y19.738+0.538
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.3333.572+3.761
TTM14.1034.001+10.102
YOY20.2845.364+14.920
5Y20.2766.009+14.267
10Y19.7386.287+13.451

1.4. Solvency of Genmab A/S.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Genmab assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genmab to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Genmab assets are financed with 10.4% credit (debt) and the remaining percentage (100% - 10.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Genmab A/S:

  • The MRQ is 0.104. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.107. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.104TTM0.107-0.003
TTM0.107YOY0.106+0.001
TTM0.1075Y0.098+0.009
5Y0.09810Y0.118-0.020
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1040.336-0.232
TTM0.1070.334-0.227
YOY0.1060.271-0.165
5Y0.0980.366-0.268
10Y0.1180.389-0.271
1.4.2. Debt to Equity Ratio

Measures if Genmab is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genmab to the Biotechnology industry mean.
  • A Debt to Equity ratio of 11.6% means that company has kr0.12 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genmab A/S:

  • The MRQ is 0.116. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.120. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.116TTM0.120-0.003
TTM0.120YOY0.118+0.001
TTM0.1205Y0.110+0.010
5Y0.11010Y0.145-0.035
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1160.382-0.266
TTM0.1200.397-0.277
YOY0.1180.341-0.223
5Y0.1100.432-0.322
10Y0.1450.465-0.320

2. Market Valuation of Genmab A/S

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Genmab generates.

  • Above 15 is considered overpriced but always compare Genmab to the Biotechnology industry mean.
  • A PE ratio of 54.99 means the investor is paying kr54.99 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genmab A/S:

  • The EOD is 51.805. Based on the earnings, the company is expensive. -2
  • The MRQ is 54.995. Based on the earnings, the company is expensive. -2
  • The TTM is 34.250. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD51.805MRQ54.995-3.190
MRQ54.995TTM34.250+20.745
TTM34.250YOY51.536-17.286
TTM34.2505Y70.529-36.279
5Y70.52910Y-28.915+99.444
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD51.805-2.262+54.067
MRQ54.995-2.599+57.594
TTM34.250-2.674+36.924
YOY51.536-4.133+55.669
5Y70.529-6.258+76.787
10Y-28.915-6.171-22.744
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Genmab A/S:

  • The EOD is 20.657. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 21.929. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 46.443. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD20.657MRQ21.929-1.272
MRQ21.929TTM46.443-24.514
TTM46.443YOY77.251-30.808
TTM46.4435Y60.893-14.450
5Y60.89310Y71.036-10.143
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.657-2.913+23.570
MRQ21.929-3.275+25.204
TTM46.443-3.508+49.951
YOY77.251-5.620+82.871
5Y60.893-8.306+69.199
10Y71.036-8.854+79.890
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Genmab is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.45 means the investor is paying kr4.45 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Genmab A/S:

  • The EOD is 4.196. Based on the equity, the company is fair priced.
  • The MRQ is 4.454. Based on the equity, the company is fair priced.
  • The TTM is 5.477. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.196MRQ4.454-0.258
MRQ4.454TTM5.477-1.024
TTM5.477YOY6.624-1.147
TTM5.4775Y7.198-1.721
5Y7.19810Y10.288-3.090
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.1961.858+2.338
MRQ4.4542.090+2.364
TTM5.4772.091+3.386
YOY6.6242.866+3.758
5Y7.1983.488+3.710
10Y10.2883.836+6.452
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Genmab A/S compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--7.51416.889-56%19.217-61%18.034-58%11.843-37%
Book Value Per Share--483.849452.242+7%384.047+26%317.151+53%191.639+152%
Current Ratio--13.34113.522-1%13.901-4%14.231-6%12.576+6%
Debt To Asset Ratio--0.1040.107-2%0.106-1%0.098+6%0.118-12%
Debt To Equity Ratio--0.1160.120-3%0.118-2%0.110+6%0.145-20%
Dividend Per Share----0%-0%-0%-0%
Eps--9.79620.892-53%20.935-53%15.933-39%9.8210%
Free Cash Flow Per Share--24.56726.675-8%13.630+80%15.136+62%8.554+187%
Free Cash Flow To Equity Per Share--24.23124.379-1%10.639+128%16.626+46%10.034+141%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--2665.105--------
Intrinsic Value_10Y_min--604.546--------
Intrinsic Value_1Y_max--93.291--------
Intrinsic Value_1Y_min--38.942--------
Intrinsic Value_3Y_max--412.736--------
Intrinsic Value_3Y_min--136.438--------
Intrinsic Value_5Y_max--891.847--------
Intrinsic Value_5Y_min--254.487--------
Market Cap132088446000.000-7%140786936575.000161326865299.750-13%167557537240.000-16%143470325530.150-2%100412019869.075+40%
Net Profit Margin--0.1370.247-45%0.390-65%0.341-60%0.401-66%
Operating Margin---0.127-100%0.431-100%0.335-100%0.395-100%
Operating Ratio--0.6700.705-5%0.595+13%0.636+5%0.591+13%
Pb Ratio4.196-6%4.4545.477-19%6.624-33%7.198-38%10.288-57%
Pe Ratio51.805-6%54.99534.250+61%51.536+7%70.529-22%-28.915+153%
Price Per Share2030.000-6%2155.0002458.000-12%2541.000-15%2184.100-1%1532.770+41%
Price To Free Cash Flow Ratio20.657-6%21.92946.443-53%77.251-72%60.893-64%71.036-69%
Price To Total Gains Ratio270.172-6%286.808-39.203+114%224.490+28%223.533+28%294.142-2%
Quick Ratio--7.33314.103-48%20.284-64%20.276-64%19.738-63%
Return On Assets--0.0180.032-44%0.048-62%0.042-57%0.044-59%
Return On Equity--0.0200.036-44%0.054-62%0.047-57%0.050-59%
Total Gains Per Share--7.51416.889-56%19.217-61%18.034-58%11.843-37%
Usd Book Value--4513908000.0004236411900.000+7%3616374300.000+25%2974790336.280+52%1794610986.210+152%
Usd Book Value Change Per Share--1.0732.412-56%2.744-61%2.575-58%1.691-37%
Usd Book Value Per Share--69.09464.580+7%54.842+26%45.289+53%27.366+152%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--1.3992.983-53%2.990-53%2.275-39%1.4020%
Usd Free Cash Flow--229194000.000250042800.000-8%128341500.000+79%142200240.000+61%80259958.170+186%
Usd Free Cash Flow Per Share--3.5083.809-8%1.946+80%2.161+62%1.221+187%
Usd Free Cash Flow To Equity Per Share--3.4603.481-1%1.519+128%2.374+46%1.433+141%
Usd Market Cap18862230088.800-7%20104374542.91023037476364.804-13%23927216317.872-16%20487562485.705-2%14338836437.304+40%
Usd Price Per Share289.884-6%307.734351.002-12%362.855-15%311.889-1%218.880+41%
Usd Profit--91392000.000155366400.000-41%197135400.000-54%141414840.000-35%87941866.320+4%
Usd Revenue--668018400.000588121800.000+14%521041500.000+28%392899920.000+70%229258691.970+191%
Usd Total Gains Per Share--1.0732.412-56%2.744-61%2.575-58%1.691-37%
 EOD+4 -4MRQTTM+11 -22YOY+15 -185Y+14 -1910Y+18 -15

3.2. Fundamental Score

Let's check the fundamental score of Genmab A/S based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1551.805
Price to Book Ratio (EOD)Between0-14.196
Net Profit Margin (MRQ)Greater than00.137
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than17.333
Current Ratio (MRQ)Greater than113.341
Debt to Asset Ratio (MRQ)Less than10.104
Debt to Equity Ratio (MRQ)Less than10.116
Return on Equity (MRQ)Greater than0.150.020
Return on Assets (MRQ)Greater than0.050.018
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Genmab A/S based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.156
Ma 20Greater thanMa 502,056.375
Ma 50Greater thanMa 1002,020.160
Ma 100Greater thanMa 2002,049.235
OpenGreater thanClose2,017.000
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in DKK. All numbers in thousands.

Summary
Total Assets35,289,000
Total Liabilities3,679,000
Total Stockholder Equity31,610,000
 As reported
Total Liabilities 3,679,000
Total Stockholder Equity+ 31,610,000
Total Assets = 35,289,000

Assets

Total Assets35,289,000
Total Current Assets33,139,000
Long-term Assets2,150,000
Total Current Assets
Cash And Cash Equivalents 14,867,000
Short-term Investments 13,268,000
Net Receivables 4,947,000
Inventory 57,000
Total Current Assets  (as reported)33,139,000
Total Current Assets  (calculated)33,139,000
+/-0
Long-term Assets
Property Plant Equipment 1,641,000
Long Term Investments 134,000
Long-term Assets  (as reported)2,150,000
Long-term Assets  (calculated)1,775,000
+/- 375,000

Liabilities & Shareholders' Equity

Total Current Liabilities2,484,000
Long-term Liabilities1,195,000
Total Stockholder Equity31,610,000
Total Current Liabilities
Total Current Liabilities  (as reported)2,484,000
Total Current Liabilities  (calculated)0
+/- 2,484,000
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt770,000
Long-term Liabilities  (as reported)1,195,000
Long-term Liabilities  (calculated)770,000
+/- 425,000
Total Stockholder Equity
Retained Earnings 19,023,000
Total Stockholder Equity (as reported)31,610,000
Total Stockholder Equity (calculated)19,023,000
+/- 12,587,000
Other
Capital Stock66,000
Common Stock Shares Outstanding 65,330
Net Invested Capital 31,610,000
Net Working Capital 30,655,000
Property Plant and Equipment Gross 2,317,000



Balance Sheet

Currency in DKK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
2,221,534
2,081,365
1,954,929
2,458,246
2,481,601
2,202,563
2,052,818
1,672,901
1,564,432
1,459,576
1,417,866
1,772,128
1,692,886
1,754,706
1,675,996
1,797,023
1,731,527
2,791,482
2,717,904
2,830,889
2,866,681
3,175,247
3,283,766
3,501,141
3,902,548
3,911,133
4,128,273
4,353,053
5,238,236
5,405,594
6,028,515
5,895,194
6,602,942
6,783,115
7,199,663
7,403,733
8,460,999
8,734,717
8,977,313
13,330,303
15,144,000
15,303,000
20,683,000
21,522,000
21,143,000
22,210,000
22,483,000
23,985,000
24,627,000
24,914,000
27,476,000
30,686,000
30,278,000
30,394,000
31,978,000
35,238,000
35,289,000
35,289,00035,238,00031,978,00030,394,00030,278,00030,686,00027,476,00024,914,00024,627,00023,985,00022,483,00022,210,00021,143,00021,522,00020,683,00015,303,00015,144,00013,330,3038,977,3138,734,7178,460,9997,403,7337,199,6636,783,1156,602,9425,895,1946,028,5155,405,5945,238,2364,353,0534,128,2733,911,1333,902,5483,501,1413,283,7663,175,2472,866,6812,830,8892,717,9042,791,4821,731,5271,797,0231,675,9961,754,7061,692,8861,772,1281,417,8661,459,5761,564,4321,672,9012,052,8182,202,5632,481,6012,458,2461,954,9292,081,3652,221,534000
   > Total Current Assets 
0
0
0
2,156,252
2,020,900
1,888,044
2,396,968
2,419,367
2,143,582
1,997,619
1,618,999
1,516,800
1,415,382
1,375,702
1,729,127
1,653,810
1,719,993
1,643,928
1,764,986
1,692,983
2,750,574
2,678,556
2,727,889
2,766,354
3,032,633
3,054,614
3,279,154
3,667,889
3,683,032
3,907,255
4,142,062
4,897,639
5,076,189
5,718,727
5,565,746
6,059,427
6,221,203
6,675,573
6,571,981
7,433,025
7,535,525
7,810,864
12,256,302
13,961,000
14,090,000
19,141,000
19,504,000
18,791,000
19,937,000
20,304,000
21,954,000
22,736,000
23,175,000
25,491,000
28,739,000
28,377,000
28,231,000
29,749,000
33,027,000
33,139,000
33,139,00033,027,00029,749,00028,231,00028,377,00028,739,00025,491,00023,175,00022,736,00021,954,00020,304,00019,937,00018,791,00019,504,00019,141,00014,090,00013,961,00012,256,3027,810,8647,535,5257,433,0256,571,9816,675,5736,221,2036,059,4275,565,7465,718,7275,076,1894,897,6394,142,0623,907,2553,683,0323,667,8893,279,1543,054,6143,032,6332,766,3542,727,8892,678,5562,750,5741,692,9831,764,9861,643,9281,719,9931,653,8101,729,1271,375,7021,415,3821,516,8001,618,9991,997,6192,143,5822,419,3672,396,9681,888,0442,020,9002,156,252000
       Cash And Cash Equivalents 
0
0
0
460,738
268,139
435,242
414,435
100,950
101,392
92,534
164,991
65,197
112,250
126,778
410,056
66,992
126,530
182,559
181,346
168,135
670,651
393,402
271,796
359,087
328,538
367,182
584,263
873,986
634,914
641,700
796,665
307,023
764,415
1,031,721
1,086,471
1,347,545
956,775
1,087,165
896,074
532,907
1,176,813
582,863
4,643,035
3,552,000
5,543,000
6,605,000
8,892,000
7,260,000
7,892,000
9,477,000
8,729,000
8,957,000
9,071,000
9,816,000
10,377,000
9,893,000
12,288,000
10,874,000
14,273,000
14,867,000
14,867,00014,273,00010,874,00012,288,0009,893,00010,377,0009,816,0009,071,0008,957,0008,729,0009,477,0007,892,0007,260,0008,892,0006,605,0005,543,0003,552,0004,643,035582,8631,176,813532,907896,0741,087,165956,7751,347,5451,086,4711,031,721764,415307,023796,665641,700634,914873,986584,263367,182328,538359,087271,796393,402670,651168,135181,346182,559126,53066,992410,056126,778112,25065,197164,99192,534101,392100,950414,435435,242268,139460,738000
       Short-term Investments 
0
0
0
816,910
804,683
485,003
1,272,450
1,548,309
1,343,174
1,208,266
1,048,177
1,035,422
906,011
817,394
768,554
1,436,757
1,362,841
1,364,148
1,469,913
1,388,844
1,859,115
2,190,776
2,366,712
2,301,428
2,616,596
2,590,595
2,621,343
2,619,243
2,855,608
3,120,422
3,145,808
3,614,942
3,986,210
4,183,038
4,097,431
4,075,192
4,744,397
4,983,770
4,999,349
5,573,187
5,653,459
6,368,090
6,473,814
7,419,000
7,417,000
6,177,000
8,577,000
8,819,000
10,191,000
8,398,000
10,014,000
10,381,000
10,917,000
11,799,000
13,411,000
12,431,000
12,256,000
14,010,000
13,252,000
13,268,000
13,268,00013,252,00014,010,00012,256,00012,431,00013,411,00011,799,00010,917,00010,381,00010,014,0008,398,00010,191,0008,819,0008,577,0006,177,0007,417,0007,419,0006,473,8146,368,0905,653,4595,573,1874,999,3494,983,7704,744,3974,075,1924,097,4314,183,0383,986,2103,614,9423,145,8083,120,4222,855,6082,619,2432,621,3432,590,5952,616,5962,301,4282,366,7122,190,7761,859,1151,388,8441,469,9131,364,1481,362,8411,436,757768,554817,394906,0111,035,4221,048,1771,208,2661,343,1741,548,3091,272,450485,003804,683816,910000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
136,692
165,982
97,221
113,727
136,004
220,808
94,378
89,381
105,839
87,499
96,837
73,548
174,660
192,510
145,133
199,589
975,674
325,564
503,968
381,844
636,690
520,031
604,638
676,558
1,326,931
705,253
859,911
1,139,453
2,990,000
1,130,000
6,359,000
2,035,000
2,712,000
1,854,000
2,429,000
3,211,000
3,398,000
3,187,000
3,876,000
4,951,000
6,053,000
3,687,000
4,814,000
5,432,000
4,947,000
4,947,0005,432,0004,814,0003,687,0006,053,0004,951,0003,876,0003,187,0003,398,0003,211,0002,429,0001,854,0002,712,0002,035,0006,359,0001,130,0002,990,0001,139,453859,911705,2531,326,931676,558604,638520,031636,690381,844503,968325,564975,674199,589145,133192,510174,66073,54896,83787,499105,83989,38194,378220,808136,004113,72797,221165,982136,692000000000000000
       Other Current Assets 
0
0
0
878,604
948,078
967,799
710,083
770,108
699,016
696,819
405,831
416,181
397,121
431,530
550,517
13,369
64,640
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000064,64013,369550,517431,530397,121416,181405,831696,819699,016770,108710,083967,799948,078878,604000
   > Long-term Assets 
0
0
0
65,282
60,465
66,885
61,278
62,234
58,981
55,199
53,902
47,632
44,194
42,164
43,001
39,076
34,713
32,068
32,037
38,544
40,908
39,348
103,000
100,327
142,614
229,152
221,987
234,659
228,101
221,018
210,991
340,597
329,405
309,788
329,448
543,515
561,912
524,090
831,752
1,027,974
1,199,192
1,166,449
1,074,001
1,183,000
1,213,000
1,542,000
2,018,000
2,352,000
2,273,000
2,179,000
2,031,000
1,891,000
1,739,000
1,985,000
1,947,000
1,901,000
2,163,000
2,229,000
2,211,000
2,150,000
2,150,0002,211,0002,229,0002,163,0001,901,0001,947,0001,985,0001,739,0001,891,0002,031,0002,179,0002,273,0002,352,0002,018,0001,542,0001,213,0001,183,0001,074,0011,166,4491,199,1921,027,974831,752524,090561,912543,515329,448309,788329,405340,597210,991221,018228,101234,659221,987229,152142,614100,327103,00039,34840,90838,54432,03732,06834,71339,07643,00142,16444,19447,63253,90255,19958,98162,23461,27866,88560,46565,282000
       Property Plant Equipment 
0
0
0
60,180
55,594
53,528
49,371
41,430
38,320
36,249
33,869
32,395
29,732
27,799
25,079
25,960
23,190
22,422
19,873
22,662
22,167
23,822
24,409
25,684
23,810
25,482
25,624
28,812
30,521
31,085
30,215
32,194
33,491
66,725
90,175
113,415
139,610
147,026
152,681
161,545
367,857
366,927
371,549
414,000
491,000
726,000
730,000
736,000
842,000
919,000
957,000
975,000
975,000
1,238,000
1,289,000
1,322,000
1,596,000
1,634,000
1,651,000
1,641,000
1,641,0001,651,0001,634,0001,596,0001,322,0001,289,0001,238,000975,000975,000957,000919,000842,000736,000730,000726,000491,000414,000371,549366,927367,857161,545152,681147,026139,610113,41590,17566,72533,49132,19430,21531,08530,52128,81225,62425,48223,81025,68424,40923,82222,16722,66219,87322,42223,19025,96025,07927,79929,73232,39533,86936,24938,32041,43049,37153,52855,59460,180000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
149,000
149,000
152,000
647,000
1,081,000
905,000
753,000
587,000
371,000
239,000
201,000
155,000
133,000
140,000
183,000
156,000
134,000
134,000156,000183,000140,000133,000155,000201,000239,000371,000587,000753,000905,0001,081,000647,000152,000149,000149,0000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,541
0
0
0
62,530
0
0
0
192,642
0
0
0
181,895
0
0
0
124,395
0
0
486,362
470,359
445,904
421,429
419,632
470,000
0
0
0
338,000
0
0
0
254,000
0
0
0
146,000
0
0
0
0
0000146,000000254,000000338,000000470,000419,632421,429445,904470,359486,36200124,395000181,895000192,64200062,5300002,5410000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
192,709
396,070
385,431
378,093
282,820
150,000
131,000
251,000
256,000
197,000
209,000
210,000
212,000
291,000
291,000
330,000
303,000
300,000
0
283,000
0
0
00283,0000300,000303,000330,000291,000291,000212,000210,000209,000197,000256,000251,000131,000150,000282,820378,093385,431396,070192,70900000000000000000000000000000000000000
> Total Liabilities 
0
0
0
924,342
867,415
750,681
1,311,695
1,401,534
1,244,268
1,172,310
1,138,118
1,078,014
1,032,451
1,002,987
1,403,774
1,309,699
1,266,551
1,179,894
1,283,670
1,072,004
1,027,369
967,492
897,328
833,742
587,099
514,145
461,961
415,828
389,880
379,652
418,941
411,540
399,375
589,161
428,341
330,750
263,012
338,438
324,564
446,639
607,555
690,804
815,672
1,096,000
905,000
2,812,000
3,045,000
2,022,000
2,115,000
2,231,000
2,700,000
2,431,000
2,195,000
2,994,000
4,029,000
2,837,000
3,204,000
3,223,000
4,126,000
3,679,000
3,679,0004,126,0003,223,0003,204,0002,837,0004,029,0002,994,0002,195,0002,431,0002,700,0002,231,0002,115,0002,022,0003,045,0002,812,000905,0001,096,000815,672690,804607,555446,639324,564338,438263,012330,750428,341589,161399,375411,540418,941379,652389,880415,828461,961514,145587,099833,742897,328967,4921,027,3691,072,0041,283,6701,179,8941,266,5511,309,6991,403,7741,002,9871,032,4511,078,0141,138,1181,172,3101,244,2681,401,5341,311,695750,681867,415924,342000
   > Total Current Liabilities 
0
0
0
894,338
840,830
707,884
1,274,196
1,324,611
1,174,806
1,107,108
1,074,095
976,728
935,589
927,769
1,326,900
1,183,650
1,143,394
1,056,584
1,160,827
907,502
861,563
795,522
719,395
655,968
585,607
512,712
460,528
414,395
388,447
378,219
418,941
411,540
399,375
589,161
426,792
327,121
259,295
334,864
321,132
443,349
435,704
524,558
654,766
938,000
740,000
2,009,000
2,258,000
1,253,000
1,293,000
1,351,000
1,830,000
1,568,000
1,339,000
1,944,000
2,988,000
1,823,000
1,955,000
1,993,000
2,902,000
2,484,000
2,484,0002,902,0001,993,0001,955,0001,823,0002,988,0001,944,0001,339,0001,568,0001,830,0001,351,0001,293,0001,253,0002,258,0002,009,000740,000938,000654,766524,558435,704443,349321,132334,864259,295327,121426,792589,161399,375411,540418,941378,219388,447414,395460,528512,712585,607655,968719,395795,522861,563907,5021,160,8271,056,5841,143,3941,183,6501,326,900927,769935,589976,7281,074,0951,107,1081,174,8061,324,6111,274,196707,884840,830894,338000
       Short-term Debt 
0
0
0
7,004
6,652
6,443
6,268
121,871
6,099
6,198
7,388
5,789
5,575
4,910
4,540
3,768
3,807
4,032
156,291
2,129
238
237
237
237
237
237
178
118
59
0
0
61,612
0
0
0
0
0
0
0
0
31,155
31,237
30,997
26,000
26,000
43,000
42,000
42,000
52,000
59,000
63,000
62,000
60,000
80,000
79,000
74,000
89,000
82,000
0
0
0082,00089,00074,00079,00080,00060,00062,00063,00059,00052,00042,00042,00043,00026,00026,00030,99731,23731,1550000000061,61200591181782372372372372372382,129156,2914,0323,8073,7684,5404,9105,5755,7897,3886,1986,099121,8716,2686,4436,6527,004000
       Accounts payable 
0
0
0
44,808
39,016
33,522
34,460
32,761
25,891
21,307
29,754
33,510
16,156
17,161
21,910
79,805
107,499
0
0
0
0
0
0
0
0
0
0
31,989
0
0
0
22,271
0
0
0
0
0
0
0
0
0
0
0
0
0
1,085,000
1,226,000
0
70,000
186,000
469,000
350,000
0
0
0
0
0
0
0
0
00000000350,000469,000186,00070,00001,226,0001,085,000000000000000022,27100031,9890000000000107,49979,80521,91017,16116,15633,51029,75421,30725,89132,76134,46033,52239,01644,808000
       Other Current Liabilities 
0
0
0
344,245
401,420
327,665
130,389
68,102
97,209
92,887
104,451
63,621
96,088
105,865
101,604
9,712
12,319
107,808
130,624
87,881
114,390
115,040
101,805
105,488
107,282
106,543
103,054
99,580
128,307
135,955
167,087
99,507
194,928
407,652
267,118
176,473
259,295
334,864
321,132
443,349
404,549
493,321
623,769
912,000
714,000
855,000
964,000
1,185,000
1,145,000
1,080,000
1,272,000
1,130,000
1,253,000
1,838,000
2,876,000
1,716,000
1,833,000
1,878,000
0
0
001,878,0001,833,0001,716,0002,876,0001,838,0001,253,0001,130,0001,272,0001,080,0001,145,0001,185,000964,000855,000714,000912,000623,769493,321404,549443,349321,132334,864259,295176,473267,118407,652194,92899,507167,087135,955128,30799,580103,054106,543107,282105,488101,805115,040114,39087,881130,624107,80812,3199,712101,604105,86596,08863,621104,45192,88797,20968,102130,389327,665401,420344,245000
   > Long-term Liabilities 
0
0
0
30,004
26,585
42,797
37,499
76,923
69,462
65,202
64,023
101,286
96,862
75,218
76,874
126,049
123,157
123,310
122,843
164,502
165,806
171,970
177,933
177,774
1,492
1,433
1,433
1,433
1,433
1,433
0
0
0
0
1,549
3,629
3,717
3,574
3,432
3,290
171,851
166,246
160,906
158,000
165,000
803,000
787,000
769,000
822,000
880,000
870,000
863,000
856,000
1,050,000
1,041,000
1,014,000
1,249,000
1,230,000
1,224,000
1,195,000
1,195,0001,224,0001,230,0001,249,0001,014,0001,041,0001,050,000856,000863,000870,000880,000822,000769,000787,000803,000165,000158,000160,906166,246171,8513,2903,4323,5743,7173,6291,54900001,4331,4331,4331,4331,4331,492177,774177,933171,970165,806164,502122,843123,310123,157126,04976,87475,21896,862101,28664,02365,20269,46276,92337,49942,79726,58530,004000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,432
3,290
3,577
3,435
3,292
3,000
17,000
490,000
492,000
492,000
496,000
496,000
496,000
500,000
500,000
496,000
491,000
491,000
0
509,000
0
0
00509,0000491,000491,000496,000500,000500,000496,000496,000496,000492,000492,000490,00017,0003,0003,2923,4353,5773,2903,43200000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
1,297,192
1,213,950
1,204,248
1,146,551
1,080,067
958,295
880,508
534,783
486,418
427,125
414,879
368,354
383,187
488,155
496,102
513,353
659,523
1,764,113
1,750,412
1,933,561
2,032,939
2,588,148
2,769,621
3,039,180
3,486,720
3,521,253
3,748,621
3,934,112
4,826,696
5,006,219
5,439,354
5,466,853
6,272,192
6,520,103
6,861,225
7,079,169
8,014,360
8,127,162
8,286,509
12,514,631
14,048,000
14,398,000
17,871,000
18,477,000
19,121,000
20,095,000
20,252,000
21,285,000
22,196,000
22,719,000
24,482,000
26,657,000
27,441,000
27,190,000
28,755,000
31,112,000
31,610,000
31,610,00031,112,00028,755,00027,190,00027,441,00026,657,00024,482,00022,719,00022,196,00021,285,00020,252,00020,095,00019,121,00018,477,00017,871,00014,398,00014,048,00012,514,6318,286,5098,127,1628,014,3607,079,1696,861,2256,520,1036,272,1925,466,8535,439,3545,006,2194,826,6963,934,1123,748,6213,521,2533,486,7203,039,1802,769,6212,588,1482,032,9391,933,5611,750,4121,764,113659,523513,353496,102488,155383,187368,354414,879427,125486,418534,783880,508958,2951,080,0671,146,5511,204,2481,213,9501,297,192000
   Common Stock
0
0
0
44,907
44,907
44,907
44,907
44,907
44,907
44,907
44,907
44,907
44,907
44,907
44,907
50,308
50,713
51,053
51,211
51,756
56,629
56,687
56,821
56,967
58,134
58,717
59,322
59,531
59,678
59,834
60,248
60,350
60,735
61,118
61,163
61,186
61,251
61,437
61,490
61,498
61,524
61,690
64,989
65,000
65,000
65,000
65,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
0
0
0066,00066,00066,00066,00066,00066,00066,00066,00066,00066,00066,00065,00065,00065,00065,00064,98961,69061,52461,49861,49061,43761,25161,18661,16361,11860,73560,35060,24859,83459,67859,53159,32258,71758,13456,96756,82156,68756,62951,75651,21151,05350,71350,30844,90744,90744,90744,90744,90744,90744,90744,90744,90744,90744,90744,907000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
80,322
80,305
77,731
75,778
77,180
77,224
77,731
81,322
84,101
95,824
91,778
91,715
94,476
90,109
92,544
92,163
102,883
102,790
103,270
95,071
82,080
77,189
87,524
88,588
91,707
95,674
95,710
100,386
98,000
107,000
98,000
74,000
54,000
95,000
82,000
84,000
81,000
97,000
110,000
151,000
98,000
117,000
112,000
0
0
00112,000117,00098,000151,000110,00097,00081,00084,00082,00095,00054,00074,00098,000107,00098,000100,38695,71095,67491,70788,58887,52477,18982,08095,071103,270102,790102,88392,16392,54490,10994,47691,71591,77895,82484,10181,32277,73177,22477,18075,77877,73180,30580,322000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
5,427,155
5,458,304
5,505,794
5,457,875
5,465,014
5,448,504
5,444,565
5,456,261
5,447,690
5,453,737
5,440,342
5,447,314
5,733,855
5,762,884
5,796,100
5,807,386
5,887,957
6,882,289
6,887,217
6,900,143
6,920,226
7,236,241
7,396,029
7,516,327
7,560,991
7,599,288
7,642,689
7,744,089
7,769,577
7,872,470
7,962,568
7,976,996
7,983,652
8,001,919
8,044,066
8,056,912
8,058,614
8,063,977
8,097,093
11,738,022
11,755,000
11,796,000
11,826,000
11,875,000
11,894,000
11,914,000
11,940,000
11,996,000
12,029,000
12,044,000
12,063,000
12,141,000
12,309,000
12,341,000
12,412,000
0
0
0012,412,00012,341,00012,309,00012,141,00012,063,00012,044,00012,029,00011,996,00011,940,00011,914,00011,894,00011,875,00011,826,00011,796,00011,755,00011,738,0228,097,0938,063,9778,058,6148,056,9128,044,0668,001,9197,983,6527,976,9967,962,5687,872,4707,769,5777,744,0897,642,6897,599,2887,560,9917,516,3277,396,0297,236,2416,920,2266,900,1436,887,2176,882,2895,887,9575,807,3865,796,1005,762,8845,733,8555,447,3145,440,3425,453,7375,447,6905,456,2615,444,5655,448,5045,465,0145,457,8755,505,7945,458,3045,427,155000



Balance Sheet

Currency in DKK. All numbers in thousands.




Cash Flow

Currency in DKK. All numbers in thousands.




Income Statement

Currency in DKK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue16,474,000
Cost of Revenue-226,000
Gross Profit16,248,00016,248,000
 
Operating Income (+$)
Gross Profit16,248,000
Operating Expense-11,153,000
Operating Income5,321,0005,095,000
 
Operating Expense (+$)
Research Development7,630,000
Selling General Administrative3,297,000
Selling And Marketing Expenses0
Operating Expense11,153,00010,927,000
 
Net Interest Income (+$)
Interest Income939,000
Interest Expense-27,000
Other Finance Cost-0
Net Interest Income912,000
 
Pretax Income (+$)
Operating Income5,321,000
Net Interest Income912,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)5,637,0005,917,000
EBIT - interestExpense = -27,000
4,352,000
4,379,000
Interest Expense27,000
Earnings Before Interest and Taxes (EBIT)05,664,000
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax5,637,000
Tax Provision-1,285,000
Net Income From Continuing Ops4,352,0004,352,000
Net Income4,352,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-596,000-912,000
 

Technical Analysis of Genmab
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Genmab. The general trend of Genmab is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Genmab's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Genmab A/S.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2,122 < 2,137 < 2,171.

The bearish price targets are: 1,892 > 1,825.

Tweet this
Genmab A/S Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Genmab A/S. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Genmab A/S Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Genmab A/S. The current macd is -4.18113963.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Genmab price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Genmab. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Genmab price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Genmab A/S Daily Moving Average Convergence/Divergence (MACD) ChartGenmab A/S Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Genmab A/S. The current adx is 17.56.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Genmab shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Genmab A/S Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Genmab A/S. The current sar is 2,096.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Genmab A/S Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Genmab A/S. The current rsi is 48.16. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Genmab A/S Daily Relative Strength Index (RSI) ChartGenmab A/S Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Genmab A/S. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Genmab price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Genmab A/S Daily Stochastic Oscillator ChartGenmab A/S Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Genmab A/S. The current cci is -96.98956057.

Genmab A/S Daily Commodity Channel Index (CCI) ChartGenmab A/S Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Genmab A/S. The current cmo is -6.74015956.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Genmab A/S Daily Chande Momentum Oscillator (CMO) ChartGenmab A/S Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Genmab A/S. The current willr is -58.0060423.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Genmab is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Genmab A/S Daily Williams %R ChartGenmab A/S Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Genmab A/S.

Genmab A/S Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Genmab A/S. The current atr is 56.01.

Genmab A/S Daily Average True Range (ATR) ChartGenmab A/S Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Genmab A/S. The current obv is -566,941.

Genmab A/S Daily On-Balance Volume (OBV) ChartGenmab A/S Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Genmab A/S. The current mfi is 44.61.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Genmab A/S Daily Money Flow Index (MFI) ChartGenmab A/S Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Genmab A/S.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Genmab A/S Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Genmab A/S based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.156
Ma 20Greater thanMa 502,056.375
Ma 50Greater thanMa 1002,020.160
Ma 100Greater thanMa 2002,049.235
OpenGreater thanClose2,017.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Genmab with someone you think should read this too:
  • Are you bullish or bearish on Genmab? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Genmab? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Genmab A/S

I send you an email if I find something interesting about Genmab A/S.


Comments

How you think about this?

Leave a comment

Stay informed about Genmab A/S.

Receive notifications about Genmab A/S in your mailbox!